European Pharmacopoeia guide to editions, online access and USP

European Pharmacopoeia guide to editions, access and USP

The European Pharmacopoeia (Ph. Eur.) is the official collection of legally binding quality standards for medicines and their ingredients in Europe. The EDQM (European Directorate for the Quality of Medicines & HealthCare) of the Council of Europe publishes it. Ph. Eur. is the official abbreviation, but you'll also see EP, Pharm. Eur. or EU pharmacopoeia.

As of 23 October 2026, the 12th Edition, up to Issue 12.3, is in force. The 13th Edition starts to apply on 1 January 2027.

Legal basis and who takes part

The Ph. Eur. rests on the Convention on the Elaboration of a European Pharmacopoeia, opened for signature in Strasbourg on 22 July 1964 and in force since 8 May 1974. A 1989 Protocol let the EU join, and Council Decision 94/358/EC accepted the Convention for the Community in 1994.

Members are 39 states plus the European Union. There are also 33 observers: 31 countries, Taiwan's TFDA and the WHO. Belarus and Russia are still listed, but their rights of representation have been suspended since 2022.

The UK did not leave the Ph. Eur. at Brexit. Membership comes from the Council of Europe Convention, not from the EU. The British Pharmacopoeia reproduces every Ph. Eur. monograph and marks them with a chaplet of stars.

The European Pharmacopoeia Commission

The European Pharmacopoeia Commission adopts the texts. Each member sends a national delegation of up to 3 members. The Commission decides by consensus, hands technical work to expert groups and working parties, and meets 3 times a year in Strasbourg. The next sessions are the 186th on 24-25 November 2026 and the 187th on 17-18 March 2027.

Is it mandatory?

Yes, in the EU (EUR-Lex summary). Directive 2001/83/EC, Annex I says the Ph. Eur. monographs "shall be applicable to all substances, preparations and pharmaceutical forms appearing in it." National authorities can still ask for tighter specifications when a monograph is not enough.

The directive also sets an order. The Ph. Eur. comes first, then the national pharmacopoeia of a member state. A third-country pharmacopoeia such as the USP is accepted only for a material described in neither. For veterinary medicines, Regulation (EU) 2019/6 applies from 28 January 2022. Through its Annex II, as revised by Delegated Regulation 2021/805, Ph. Eur. monographs and general chapters are applicable.

Current European Pharmacopoeia edition

From the 12th Edition, the EDQM moved to one edition per year with three issues (.1, .2, .3). That replaced the old cycle of a three-year edition plus eight supplements. There is no "12.0", and the issues are no longer called supplements (EDQM FAQ).

As of 23 October 2026, the 12th Edition up to Issue 12.3 applies. Issue 13.3 is the newest published issue, but is not yet in force. From 13.1 on, texts appear at least 9 months before they take effect, up from 6 months.

Only the current texts are legally applicable. If you searched for the European Pharmacopoeia 10th edition, or the 5th or 6th, treat that edition as a historical file, not as the text in force. For current compliance, use the in-force version on Ph. Eur. Online. The 11th Edition platform is closed (announced 10 February 2026), and old accounts did not carry over.

European Pharmacopoeia online access and login

The Ph. Eur. has been online only since Issue 12.1. The platform launched in June 2025. From 1 January 2026, subscriptions are online-only and the printed edition is discontinued.

The official texts sit on Ph. Eur. Online. Access needs a paid 365-day licence from the EDQM Store and an account login. The platform sorts texts into in force, not yet in force and no longer in force, and keeps earlier versions back to 11.0.

Two free tools help without a licence:

• The Knowledge database gives monograph numbers, revision history, ongoing work, chromatograms, reagent details, links to reference standards, and the CEP list. It does not hold the official monograph texts.
• Pharmeuropa publishes draft texts for public comment. It is free with registration.

Monographs and general chapters

The Ph. Eur. has almost 3,000 texts of four kinds:

• General Notices apply to every text. Read them before any monograph.
• General monographs cover dosage forms (tablets, parenterals) and classes of substance. Monograph 2034, Substances for pharmaceutical use, applies to all active substances, with or without their own monograph.
• Individual monographs cover active substances, excipients, biologicals, vaccines, herbal drugs, radiopharmaceuticals and homeopathic preparations.
• General chapters describe analytical methods and other topics. They become mandatory when a monograph refers to them.

Ph. Eur. tests are the reference methods if there's a dispute (EDQM presentation hosted by the EMA). You may use an alternative method if it gives the same pass/fail result and you show it is suitable.

Ph. Eur. reference standards

Ph. Eur. reference standards are the materials the monographs call for in identification, purity tests and assays. The EDQM distributes them as pharmacopoeia products: chemical reference substances (CRS), biological reference preparations (BRP), herbal reference standards (HRS) and reference spectra. There were more than 3,100 as of mid-2024.

The catalogue updates daily and shows batch validity, safety data sheets and leaflets. Orders and quotes go through the EDQM Store. Under Directive 2001/83/EC, where a Ph. Eur. monograph exists, you should use Ph. Eur. reference standards where relevant.

A related EDQM product is the certificate of suitability (CEP). After a central review of a dossier, it confirms that the relevant Ph. Eur. monographs, plus extra tests where needed, suitably control a substance's quality. It also covers TSE risk. The procedure started in 1994. A CEP is not a GMP certificate.

Ph. Eur. vs USP

The two differ most in where their legal force comes from. The USP-NF is published by the United States Pharmacopeial Convention, a private non-profit. It becomes binding because the FD&C Act names it an "official compendium" in §201(j). Under §501(b), a drug with a compendial name that falls below the compendial strength, quality or purity is adulterated unless the label plainly states the difference (FDA CPG 420.100). The Ph. Eur. is binding through an intergovernmental convention and EU law, and it is assessed in the marketing authorisation dossier.

The two are not interchangeable as a whole. The Pharmacopoeial Discussion Group (Ph. Eur., JP and USP since 1989, with the Indian Pharmacopoeia Commission joining in October 2023 and the WHO as observer) harmonises selected texts. Check their harmonisation status one text at a time. ICH Q4B addresses interchangeability of specific harmonised texts through topic annexes. These include sterility and bacterial endotoxins (EMA page). Before substituting a method, check the relevant annex, its conditions and its implementation in your market.

Recent changes

• The rabbit pyrogen test (chapter 2.6.8) was removed on 1 January 2026. Chapters 2.6.10 (Histamine) and 2.6.11 (Depressor substances) were suppressed at the same time. Chapter 5.1.13 now guides a risk-based choice of in vitro test, such as the monocyte activation test.
• Chapter 2.6.41, high-throughput sequencing for extraneous agents, applies from 1 April 2026.
• The 183rd session adopted new chapters 2.9.54 (inhaled dose, with the JP) and 2.5.43 (size-exclusion chromatography for monoclonal antibodies). It also adopted a revision adding recombinant factor C to bacterial endotoxins 2.6.14 as Method G, and started work on nitrites in excipients.
• The 184th session approved the first texts of the European Drug Shortages Formulary, plus new chapters 2.2.62 and 2.7.38.
• The 185th session put 8 new monographs and 3 new general chapters into Issue 13.3 and set up a working party on 3D-printed medicines.

RegAffairs AI answers what the European Pharmacopoeia is, which edition is current and how it differs from the USP, with a citation on each point.